Tuberc Respir Dis > Accepted Articles
DOI:    [Accepted]
Published online November 15, 2023.
Recent advances in adjuvant therapy for non–small-cell lung cancer
Mi-Hyun Kim, M.D., Ph.D.1,2, Soo Han Kim, M.D.1,2, Min Ki Lee, M.D., Ph.D.1,2, Jung Seop Eom, M.D., Ph.D.1,2
1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea
2Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
Correspondence:  Jung Seop Eom, Tel: +82-51-240-7889, Fax: +82-51-254-3127, 
Received: 27 June 2023   • Revised: 31 August 2023   • Accepted: 11 November 2023
After the successful development of targeted therapy and immunotherapy for the treatment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treatment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted therapies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunotherapy in the adjuvant treatment of early-stage NSCLC.
Key Words: Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Molecular Targeted Therapy, Immunotherapy

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2023 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next